Ocuphire Pharma and FamyGen Life Sciences have entered into a global licensing agreement that will allow Famy to fund and commercialize the development of Nyxol eye drops in the U.S. as well as globally, according to a press release.
Viatris, which recently announced that it will acquire Famy and Oyster Point Pharma, has also agreed to commercialize Nyxol following each regulatory approval.
Famy will pay $35 million in cash to Ocuphire up front under the terms of the agreement. Famy will fund the development of Nyxol through all clinical, manufacturing (Read more...)